Chile acquires Nirsevimab to combat respiratory syncytial virus (RSV)
Chile is the first country in Latin America to acquire the drug, which will help newborns and infants up to six months of age.
Health Minister Ximena Aguilera has made an important announcement, confirming that Chile will be the first country in Latin America to acquire Nirsevimab to combat respiratory syncytial virus (RSV).
The Health Ministry will implement an immunization program from March of this year for all infants under six months of age. The drug is an effective and safe monoclonal antibody against respiratory syncytial virus (RSV).
Nirsevimab is a monoclonal antibody that is administered in a single preventive dose. It has demonstrated high efficiency and safety in clinical trials, receiving approval and strong recommendation for use by the world’s leading agencies.
The virus is the main cause of hospitalization and sequelae due to respiratory viruses in children under one year of age.
This important health strategy was made possible thanks to joint work between the Institute of Complex Engineering Systems (ISCI) and the Faculty of Medicine at the Universidad de Chile, alongside the Health Ministry, in particular the Public Health Undersecretary’s Office Health Information and Statistics Department (DEIS). These institutions carried out the impact and cost-effectiveness study that demonstrated the enormous advantages that early adoption of the strategy would have.